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a b s t r a c t 
Critical-sized diaphysis defects are complicated by inherent sub-optimal healing conditions. The two- 
staged induced membrane technique has been used to treat these challenging defects since the 1980’s. It 
involves temporary implantation of a membrane-inducing spacer and subsequent bone graft defect fill- 
ing. A single-staged, graft-independent technique would reduce both socio-economic costs and patient 
morbidity. Our aim was to enable such single-staged approach through development of a strong bioac- 
tive glass scaffold that could replace both the spacer and the graft filling. We constructed amorphous 
porous scaffolds of the clinically used bioactive glass S53P4 and evaluated them in vivo using a critical- 
sized defect model in the weight-bearing femur diaphysis of New Zealand White rabbits. S53P4 scaffolds 
and standard polymethylmethacrylate spacers were implanted for 2, 4, and 8 weeks. Induced membranes 
were confirmed histologically, and their osteostimulative activity was evaluated through RT-qPCR of bone 
morphogenic protein 2, 4, and 7 (BMPs). Bone formation and osseointegration were examined using his- 
tology, scanning electron microscopy, energy-dispersive X-ray analysis, and micro-computed tomography 
imaging. Scaffold integration, defect union and osteosynthesis were assessed manually and with X-ray 
projections. We demonstrated that S53P4 scaffolds induce osteostimulative membranes and produce os- 
seointegrative new bone formation throughout the scaffolds. We also demonstrated successful stable scaf- 
fold integration with early defect union at 8 weeks postoperative in critical-sized segmental diaphyseal 
defects with implanted sintered amorphous S53P4 scaffolds. This study presents important considerations 
for future research and the potential of the S53P4 bioactive glass as a bone substitute in large diaphyseal 
defects. 
Statement of significance 
Surgical management of critical-sized diaphyseal defects involves multiple challenges, and up to 10% re- 
sult in delayed or non-union. The two-staged induced membrane technique is successfully used to treat 
these defects, but it is limited by the need of several procedures and bone graft. Repeated procedures 
increase costs and morbidity, while grafts are subject to donor-site complications and scarce availability. 
To transform this two-staged technique into one graft-independent procedure, we developed amorphous 
porous scaffolds sintered from the clinically used bioactive glass S53P4. This work constitutes the first 
evaluation of such scaffolds in vivo in a critical-sized diaphyseal defect in the weight-bearing rabbit fe- 
mur. We provide important knowledge and prospects for future development of sintered S53P4 scaffolds 
as a bone substitute. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. 
This is an open access article under the CC BY-NC-ND license 
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Historically, large bone defects often had only one, life- 
hanging, solution: amputation [1] . Fortunately, modern-day clin- 
cians can utilize the body’s natural bone healing capacity using 
ell-formulated principles. A well-known set of such principles is 
he ‘diamond concept’ and its revision titled the “hexagon of bone 
ealing”, according to which successful fracture healing requires 
nflammatory cells and mediators, growth factors, osteogenic stem 
ells, an osteoconductive scaffold, a mechanically stable environ- 
ent, and vascularity [2 , 3] . Yet, natural healing is highly depen- 
ent on fracture size and location, with critical-sized diaphyseal 
efects still posing a major challenge for surgeons and patients. 
‘Critical-sized’ defects generally do not heal spontaneously with 
urgical stabilization and require further intervention, regardless of 
tiology [4] . In these defects, the natural healing process is under- 
ined by extensive bone loss, defect displacement causing vascular 
isruption, high demand for mechanical stability due to functional 
oading, and the inherently inferior healing conditions in the dia- 
hysis [5 , 6] . Consequently, up to 10% result in delayed unions or 
on-unions [7] . 
In the 1980s, Alain Masquelet developed a two-staged induced 
embrane (IM) technique to treat these challenging defects [8] . 
his commonly used method involves two procedures. First, the 
efect is debrided and a polymethylmethacrylate (PMMA) spacer 
s implanted to elicit a foreign body-derived reaction resulting in a 
ioactive IM. This defect-enclosing IM is then carefully incisioned 
–8 weeks later, the spacer is removed, and the IM is filled with 
one graft [9–12] . 
In the IM technique, the role of the temporary PMMA spacer 
s to produce the IM. PMMA is not a bone substitute and will not 
e replaced by new bone. Thus, the PMMA spacer needs to be re- 
oved before the bone graft can be placed in the IM to act as a
caffold f or bone ingrowth and heal the defect [13] . The IM pre-
ents graft resorption and optimizes the local healing conditions 
y providing stability and vascularity. It also provides stem cells 
nd osteogenic growth factors, such as bone morphogenic proteins 
BMPs) [14 , 15] . Notably, BMP-2 is important in osteogenic differen- 
iation of mesenchymal progenitor cells and initiation of the frac- 
ure healing cascade, while BMP-4 and BMP-7 are key stimulators 
f osteoblasts and callus formation [16 , 17] . 
This utilization of the body’s own signaling systems is one of 
he core benefits of the IM technique as it bypasses problems re- 
ated to dosage, release patterns and adverse effects, which limits 
any manufactured drug delivery-systems [18] . The IM has been 
escribed as the ideal ‘biological chamber’ for the ‘diamond con- 
ept’ as it gathers its fracture-healing components [19] , and several 
linical studies have found this approach suitable for large defects 
n long bones [20–22] . 
However, the IM technique is limited by its two-staged na- 
ure and graft-dependence. Repeated surgeries infer higher socio- 
conomic costs and expose patients to prolonged hospitalization 
nd morbidity. Autografts, while being the graft gold standard, are 
imited by donor-site complications and scarce availability – espe- 
ially so in large defects [23] . We hypothesised that a mechanically 
table scaffold crafted from an osteostimulative and osteoconduc- 
ive bone substitute that can induce an active IM and integrate in 
he defect would be a promising solution to both problems. 
Consequently, we developed a scaffold aimed to enable a 
raft-independent single-staged IM technique for the treatment of 
ritical-sized diaphyseal defects. This amorphous porous scaffold is ∗ Corresponding author at: University of Helsinki, Helsinki University Hospital, 
/o Nina Lindfors, Topeliuksenkatu 5B, 00260 Helsinki, Finland. 






464 intered from the bioactive glass S53P4 (BAG-S53P4). Hench and 
aschall [24 , 25] introduced BAG in the 1960s, and it has received 
ast interest as a bone graft substitute. Despite being a silica-based 
aterial, it can bond firmly to living tissue in the body. Upon im- 
lantation, this bonding is initiated through a rapid exchange of 
a + ions in the BAG with H + and H 3 O + ions in body fluids, re-
ulting in a silica-rich reaction surface on the BAG. This surface 
hen attracts calcium and phosphate which precipitates into cal- 
ium phosphate (CaP) and crystallizes into hydroxyapatite. As hy- 
roxyapatite resembles the natural bone mineral, it forms strong 
onds with bone apatite. This surface transformation makes BAG 
steoconductive and osseointegrative [26 , 27] . Furthermore, BAG’s 
steostimulative dissolution products promote osteoprogenitor cell 
aturation and gene expressions vital in osteogenesis and angio- 
enesis [28 , 29] . 
S53P4 is a BAG with non-antibiotic antimicrobial traits [30 , 31] . 
ts granular form has been clinically used since the 1990s, with 
uccessful application in chronic osteomyelitis, trauma, and bone 
umours [32–34] . Utilization of BAG-S53P4 in the IM technique is 
 promising concept. Recently, Tanner et al. [35] initiated a clini- 
al trial evaluating loose BAG-S53P4 granules as a bone graft re- 
lacement in large tibial and femoral defects treated with the 
wo-staged IM technique. Still, this trial only addressed the graft- 
ependence and did not aim to eliminate the need of repeated 
urgeries. The initial PMMA spacer implantation is still needed. 
Previous research on a single-staged IM technique shows that 
intered non-amorphous BAG-S53P4 scaffolds implanted in me- 
hanically stable, non-critical metaphyseal defects in New Zealand 
hite rabbits produce new bone and IMs expressing osteogenic 
nd angiogenic growth factors [36 , 37] . However, the IM technique 
s mainly used to treat critical-sized diaphyseal defects, which are 
ore complex [8–12] . These unstable defects need surgical fixation 
nd do not provide a protecting scaffold-enclosure, as the drilled- 
ut metaphyseal defects did. Thus, bone-substituting scaffolds used 
n critical-sized diaphyseal defects must be strong and resistant. It 
as been considered difficult to sinter BAGs into strong scaffolds, 
ut recent years has brought a greater understanding of how to 
educe the brittleness of the glass through sintering optimization 
38] . 
This preclinical study was designed to test our hypothesis. We 
valuated amorphous porous BAG-S53P4 scaffolds in vivo using a 
ingle-staged IM technique to treat critical-sized segmental defects 
n the femur diaphysis of New Zealand White rabbits . We studied 
he scaffold’s capability to (1) form IMs similar to those induced 
y standard PMMA spacers, (2) promote osteogenesis through IM 
xpressions of key BMPs in comparison with the expressions in 
MMA IMs, and (3) achieve stable scaffold integration through os- 
eointegrative new bone formation with successful osteosynthesis 
nd early defect union. 
. Material and methods 
.1. Materials 
.1.1. Bioactive glass S53P4 scaffolds 
We used BAG-S53P4 granules of size fraction 315–500 μm 
Bonalive Biomaterials, Turku, Finland) to develop amorphous scaf- 
olds robust enough for application in large weight-bearing long 
one defects. The wt. % composition of BAG-S53P4 is 53% SiO 2 , 23% 
a 2 O, 20% CaO, 4% P 2 O 5 , and its density is 2.66 kg/dm 
3 [39] . The
ranules were sintered using pressureless sintering into cylindrical 
hapes under carefully controlled conditions in uncovered graphite 
olds at 630 °C for 60 min in a nitrogen atmosphere in a tubu- 
ar oven. The amorphous porous BAG-S53P4 scaffolds ( Fig. 1 ) mea- 
ured 10 mm × 10 mm with an average mass of 831 mg. The scaf- 
old porosity was 50.0 ± 3.0% and the compressive strength of dry 
E. Eriksson, R. Björkenheim, G. Strömberg et al. Acta Biomaterialia 126 (2021) 463–476 
Fig. 1. Images depicting the macroscopic and microscopic structure of the realized sintered BAG-S53P4 scaffolds pre-implantation. A: Representative photo of a 
10 mm × 10 mm BAG-S53P4 scaffold. B–C: SEM backscattered electron images of a BAG-S53P4 scaffold cut in the transversal plane, without magnification (B) and with 









































caffolds was 4.80 ± 0.60 MPa (mean ± standard error of the mean 
SEM)) [40] . Compared to porous BAG-S53P4 scaffolds described in 
arlier literature, the strength of our scaffolds are 10 times higher 
41] and corresponds to the values (2–10 MPa) reported for tra- 
ecular bone [42] . Measurement through micro-computed tomog- 
aphy of a BAG-S53P4 scaffold with a porosity of 49.8% rendered 
 mean pore size of 0.19 ± 0.07 mm (mean ± standard deviation), 
ith a maximum pore size of 0.51 mm, and a mean neck diameter 
f 0.23 ±0.18 mm. Scaffolds were sterilized using gamma irradia- 
ion with a dose of 25 kGy. 
.1.2. Standard polymethylmethacrylate spacers 
Cylindrical, non-porous (compact) PMMA (Palacos R + G, 
eraeus Medical GmbH, Wehrheim, Germany) spacers of 
0 mm × 10 mm in size were constructed under sterile con- 
itions according to the manufacturer’s instructions and sterilized 
n an autoclave prior to implantation. 
.2. In vivo experimental animal model 
All protocols were approved by the National Animal Experimen- 
al Board of Finland (permit number: ESAVI/6423/04.10.07/2017) 
nd conducted in compliance with the principles established at 465 he University of Helsinki, the ARRIVE guidelines, and the Direc- 
ive 2010/63/EU of the European Parliament and the Council of the 
uropean Union. 
A critical-sized, weight-bearing diaphyseal defect model was 
esigned using 18 female New Zealand White (NZW) rabbits (Har- 
an laboratories, The Netherlands) in three parallel experiments 
ith study endpoints at 2, 4, and 8 weeks. Each experiment in- 
luded an experimental BAG-S53P4 scaffold group ( n = 3) and a 
tandard PMMA spacer group ( n = 3). In total, BAG-S53P4 scaffolds 
nd PMMA spacers were allocated to nine rabbits each ( n = 9 for 
ach). At study initiation, the rabbits were skeletally mature (aged 
0–11 months) with body weights (mean ± SEM) of 3.3 ± 0.1 kg 
BAG-S53P4 groups) and 3.6 ± 0.1 kg (PMMA groups). Allocation 
o the parallel experiments was made according to the supplier- 
rovided rabbit identification numbers. Scaffolds were allocated 
sing a computer-based random number generator and block ran- 
omization. Animal care staff were blinded to allocation, but in- 
estigators were not blinded. 
The implantation procedures were initiated using medetomi- 
ine hydrochloride (Cepetor, 0.5 mg/kg s.c.) and ketamine hy- 
rochloride (Ketalar, 25 mg/kg s.c.) to put the non-fasting animals 
nder general anesthesia in their cages to minimize stress. Preop- 
rative buprenorphine (Vetergesic, 0.05 mg/kg s.c. ×1), cefuroxime 





























































Primer sequences used in RT-qPCR analysis of relative gene expressions in tissue 
samples from induced membranes of BAG-S53P4 scaffolds and PMMA spacers. 
Gene Primer Primer sequence (5 ′ –3 ′ ) Bp. Acc. No. 
GAPDH Forward TGGTGAAGGTCGGAGTGAAC 89 NM_001082253 
Reverse GGCGACAACATCCACTTTGC 
BMP-2 Forward CAGCGGAAACGCCTCAAATC 224 NM_001082650 
Reverse ACACAGCATGCCTTCGGAAT 
BMP-4 Forward TGAGGAGCTTCCACCACGAA 109 NM_001195723 
Reverse ATGGCCTCGTTCTCTGGGAT 
















































Zinacef, 40 mg/kg s.c. ×1), and carprofen (Rimadyl, 4 mg/kg s.c. 
1) was administered to prevent pain and infection. The femoral 
rea was shaved, and animals were placed in standard decubitus 
osition in the semi-sterile operation room. A lateral approach ex- 
osed the femur using standard sterile procedures. A 1 cm long 
egment of the mid-diaphysis was removed with a surgical saw, 
nd the defect gap was filled with a BAG-S53P4 scaffold or a 
MMA spacer. The 1 cm defect size corresponds to 100% of the fe- 
ur circumference and has been verified not to heal spontaneously 
43–45] . A rigid fixation of the femur was achieved using a 59 mm 
ong 8-hole locking compression plate (Veterinary Instrumentation, 
heffield, United Kingdom). The plate was placed on the femur 
ver the BAG-S53P4 scaffold or the PMMA spacer and attached to 
he bone with three 2.4-mm screws on each side of the implant. 
 1 mm stainless-steel wire was then placed around the implant 
nd the plate to prevent implant displacement. Sutures closed the 
ound. Perioperative corneal drying and heat loss were prevented 
ith ophthalmic ointment and heating pads, respectively. After im- 
lantation, the preoperative buprenorphine and cefuroxime admin- 
stration was repeated. 
Postoperatively, Cefuroxime (Zinacef, 40 mg/kg s.c. ×3), 
uprenorphine (Vetergesic, 0.01 mg/kg s.c. ×2), and carprofen (Ri- 
adyl, 4 mg/kg s.c. ×1) were given for three days to provide anal- 
esia and prevent infection. The animals had free mobility in their 
ages and were monitored closely by skilled animal care staff. To 
ecure humane endpoints, animals showing signs of pre- or post- 
perative complications were switched to an earlier study end- 
oint without any further result assessment or were excluded from 
he study. Two rabbits in the overall PMMA group were switched 
ith rabbits at earlier endpoints due to postoperative wound in- 
ection. One rabbit in the 2-week PMMA group was excluded due 
o unexplained preoperative vaginal bleed. Hence, n = 8 for that 
roup. The study included 17 rabbits post exclusion. 
At 2, 4, and 8 weeks postoperative, corresponding animals were 
ut under general anesthesia in their cages using the already de- 
cribed method and euthanized using a pentobarbital overdose 
Mebunat Vet, 60 mg/kg i.p. ×1). Femurs, implants, and surround- 
ng membranes were collected. Samples for histochemical analysis 
nd imaging were stored in 10% formalin overnight, washed, and 
tored in 70% EtOH. Samples for RT-qPCR analysis were stored in 
NA later solution (Invitrogen, USA) in + 4 °C overnight and then 
tored in sterile tubes in −80 °C. 
.3. Histology 
.3.1. Hematoxylin and eosin staining 
Tissue samples of IMs from BAG-S53P4 scaffolds and PMMA 
pacers were stained with hematoxylin and eosin ( H&E) and his- 
ologically examined. Samples were prepared using a KOS multi- 
unctional microwave tissue processor (Milestone Srl, Sorisole BG, 
taly) and embedded in paraffin blocks using a Microm EC 350 Tis- 
ue Embedding Center (Thermo Scientific, MI, USA). A Motorized 
otary Microtome Leica RM2255 (Leica Microsystems, Wetzlar, Ger- 
any) cut the blocks into 3-μm sections, which were then deparaf- 
nized in xylene and hydrated to water in a descending alcohol 
eries using a Varistain XY robotic slide stainer (Thermo Scientific, 
heshire, England). A 10-min incubation in hematoxylin stained 
ell nuclei, and a 5-min incubation in eosin stained cytoplasm and 
xtracellular matrix. Stained sections were dehydrated in an as- 
ending alcohol series, cleared by immersion in xylene, mounted, 
nd analysed using a Leica DM60 0 0 B/M light microscope with a 
igital camera (Leica Microsystems, Wetzlar, Germany). 
.3.2. Goldner’s Masson trichrome staining 
Resected femurs with implanted BAG-S53P4 scaffolds were 
ransversally cut with a diamond saw, stained with Goldner’s Mas- 466 on trichrome stain, and examined. Cut segments were processed 
nd stained at BioSiteHisto Ltd. (Helsinki, Finland). Images were 
enerated using 3DHISTECH Pannoramic 250 FLASH II digital slide 
canner at Genome Biology Unit supported by HiLIFE and the Fac- 
lty of Medicine, University of Helsinki, and Biocenter Finland. 
istopatohological changes were assessed by a professional pathol- 
gist at the Finnish Centre for Laboratory Animal Pathology (De- 
artment of Veterinary Biosciences, University of Helsinki, Finland). 
.4. Real-time quantitative polymerase chain reaction analysis 
Relative gene expressions in IMs from BAG-S53P4 scaffolds and 
MMA spacers were analyzed using real-time quantitative poly- 
erase chain reaction (RT-qPCR). IM tissue samples of 30–50 mg 
ere homogenized (speed 6.5, 2 × 20 s) in 300 ml RLT + buffer 
olution with 10 μl β-mercaptoethanol (Bio-Rad/Life Science Re- 
earch, USA) per 1 ml buffer using a FastPrep-24 TM Homogenizer 
MP Biomedicals, USA) and Precellys Lysing Kit CK28 (Bertin In- 
truments, France). Liquid phase with total RNA was pretreated 
ith 10 μl Proteinase K (Qiagen, CA, USA) in 590 μl RNase free 
ater and isolated using RNeasy Plus Mini Kit (Qiagen, CA, USA). 
 NanoDrop 10 0 0 spectrophotometer (Thermo Scientific, Wilming- 
on, DE) was used to measure total RNA, and its integrity was as- 
essed using denaturing agarose gel analysis with Ethidium Bro- 
ide (Amresco, Solon, OH) staining. Isolated RNA (20 0 0 ng per 
ample) was reverse transcribed into cDNA using iScript TM cDNA 
ynthesis kit (Bio-Rad, CA, USA) and diluted 1:5 with RNase- 
ree water. A LightCycler96 real-time PCR System (Roche, Basel, 
witzerland) was used to perform RT-qPCR in duplicate wells with 
 reaction mixture containing iQ TM SYBR® Green supermix reagent 
Bio-Rad/Life Science Research), 20 ng sample cDNA, and primer 
air mix ( Table 1 ). Negative controls contained RNase-free wa- 
er instead of cDNA. The housekeeping gene Glyceraldehyde-3- 
hosphate Dehydrogenase (GAPDH) was used for relative quantifi- 
ation. Relative gene expressions were calculated from RT-qPCR re- 
ults using the Gene Expression Macro (Bio-Rad/Life Science Re- 
earch, version 1.1) and the comparative Ct method [46] . 
.5. Manual assessment and X-ray imaging 
Segmental defects with implanted BAG-S53P4 scaffolds were 
ssessed manually in situ and after femur resections at 2, 4, and 
 weeks to evaluate achieved scaffold integration, state of the os- 
eosynthesis, and signs of early defect union. Manual assessments 
ere supplemented by X-ray imaging (Phoenix Xray Systems & 
ervices GmbH, Germany) of resected femurs. Each defect with an 
mplanted BAG-S53P4 scaffold was qualitatively assessed as ‘Full 
ntegration’, ‘Partial integration’, or ‘Not integrated’. Samples as- 
essed as ‘Full integration’ presented a stably integrated BAG-S53P4 
caffold, a successful osteosynthesis with sufficient alignment and 
igns of early union in both defect ends, in situ as well as after re-
ection. Samples assessed as ‘Partial integration’ fulfilled the ‘Full 
























































Fig. 2. Representative overview of the intra-operative process. Photos taken of a 
BAG-S53P4 scaffold (A) during implantation in the segmental defect created in the 
mid-shaft of a rabbit femur, (B) in situ prior to femur resection at 8 weeks postop- 
erative, and (C) in the resected femur at 8 weeks postoperative. An induced mem- 
brane can be seen enclosing the well-aligned defect and the integrated BAG-S53P4 





















ntegration’ criteria in only one defect end or presented scaffold 
islocation, but not detachment, during or after resection. In ‘Not 
ntegrated’ samples, the scaffolds det ached completely during or 
fter resection. 
.6. Scanning electron microscopy imaging and energy-dispersive 
-ray analysis 
Resected femurs with implanted BAG-S53P4 scaffolds were 
ransversally cut into 3 mm thick discs using a diamond saw 
nd subject to scanning electron microscopy (SEM) and energy- 
ispersive X-ray analysis (EDXA). Discs cut from the longitu- 
inal end area of the implanted scaffolds were cast in epoxy 
esin, ground, and polished. Panoramic cross-sectional SEM images 
ere taken with a LEO 1530 Gemini SEM instrument (Carl Zeiss, 
berkochen, Germany) with an acceleration voltage of 20 kV at 
p to 75 × magnification using Polaroid 545 as reference. The quad 
ack scatter detector was in Composition mode and with BSD Gain 
djusted to ‘high’. EDXA (UltraDry Silicon Drift Detector, Thermo 
cientific, Wisconsin, US) enabled elemental identification of re- 
ction surface layers inside the BAG-S53P4 scaffolds. Two 2-week 
nd one 4-week scaffold were excluded from SEM and EDXA due to 
etachment during femur resection, which compromised the sam- 
le cutting process. 
.7. Micro-computed tomography imaging and ImageJ area 
easurement 
Micro-computed tomography imaging (μCT) scans of resected 
emurs and BAG-S53P4 scaffolds were obtained using a Nanotom 
80 NF apparatus (Phoenix X-Ray Systems & Services GmbH, Ger- 
any) with 15 μm image resolution. Image artifacts from metal- 
ic fixation were effectively removed with a threshold adapted bi- 
ary mask and background subtraction utilizing the Rolling Ball- 
lgorithm with a radius of approximately 1.50 mm (ImageJ, ver- 
ion 1.52p). Transversal series of μCT images, approximately 0.25 
o 0.45 mm apart, were created from each scan. The μCT images 
ere sectioned according to their placement in the scaffold ends or 
iddle, with each section representing 33% (3.3 mm in length) of 
he whole scaffold. End sections were grouped together in subse- 
uent analysis as the proximal/distal orientation could not always 
e reliably determined. 
Areas corresponding to the whole BAG-S53P4 scaffold, remain- 
ng BAG-S53P4, and formed reaction surface and new bone inside 
he scaffold were measured by thresholding for applicable grey 
alues in the μCT images using ImageJ software (version 1.53d). 
ecure thresholding separation of reaction surface and new bone 
ould not be established, and these areas were therefore measured 
ogether. Tissue external to the implanted scaffold, such as formed 
allus and diaphysis ends, were excluded to only measure areas in- 
ide the BAG-S53P4 scaffolds. Area measurements were completed 
y one author (E.E.) at two different time points and the resulting 
verage values were used for statistical analysis. 
.8. Statistical analysis 
Statistical analyses were performed using Prism software 
GraphPad Software, Inc., version 8.0.0). Relative gene expressions 
n IMs of BAG-S53P4 scaffolds and PMMA spacers, and μCT image 
rea measurements of BAG-S53P4 scaffolds were analyzed using 
ne-way ANOVA [47] followed by Tukey’s post hoc test [48] for 
omparison of the implant types at 2, 4, and 8 weeks. Unpaired t - 
ests [47] were used to compare relative gene expressions in BAG- 
53P4 IMs with PMMA IMs. Nonparametric Mann–Whitney U tests 
48] were used to compare μCT image area measurements in the 467 nd and middle sections of BAG-S53P4 scaffolds. Underlying as- 
umptions of data normality and equality for ANOVA and t -tests 
ere evaluated with Q-Q-plots and F-tests [49] . The threshold of 
tatistical significance was p < 0.05. Results are presented as mean 
SEM. 
. Results 
.1. Histological assessment of induced membranes 
.1.1. BAG-S53P4 scaffolds form induced membranes around 
ritical-sized diaphyseal defects 
During the sample collection procedures at 2, 4, and 8 weeks 
ostoperative, we found that defect-enclosing IMs had formed in 
ll femur samples with implanted BAG-S53P4 scaffolds ( Fig. 2 ) or 
MMA spacers. Analysis of H&E-stained tissue samples confirmed 
hat IMs of BAG-S53P4 and PMMA were structurally similar and 
ormed a distinct interface adjacent to the implant ( Fig. 3 ). 
.2. RT-qPCR and analysis of relative gene expressions in induced 
embranes 
.2.1. Expressions of BMP-2, -4, and -7 are upregulated in 
embranes induced by BAG-S53P4 
RT-qPCR confirmed upregulated expressions of BMP-2, -4, and 
7 in IMs of both BAG-S53P4 scaffolds and PMMA spacers at 2, 4, 
nd 8 weeks, but the expression patterns differed ( Fig. 4 ). 
E. Eriksson, R. Björkenheim, G. Strömberg et al. Acta Biomaterialia 126 (2021) 463–476 
Fig. 3. Membranes induced by BAG-S53P4 scaffolds and PMMA spacers. A: Photo showing a representative induced membrane (IM, indicated by a black arrow) formed 
around an 8-week BAG-S53P4 scaffold cut in the transversal plane in the longitudinal end region of the scaffold after femur resection. B–D: Representative H&E-stained 
tissue samples from induced membranes formed around PMMA spacers (left) and BAG-S53P4 scaffolds (right) at 2 (B), 4 (C), and 8 weeks (D). A single asterisk ( ∗) indicates 































BMP-2 expression in BAG-S53P4 IMs peaked at 2 weeks and 
hen decreased evenly throughout 4 and 8 weeks. In contrast, 
MP-2 in PMMA IMs increased from a low expression at 2 weeks 
nd peaked at week 4 and 8. The only significant difference was 
t 8 weeks, when PMMA IMs presented higher BMP-2 expression 
han BAG-S53P4 IMs (3.8 ± 0.6 vs. 1.2 ± 0.7, p = 0.045). 
BMP-4 expression in BAG-S53P4 IMs was persistently upregu- 
ated at 2 and 4 weeks and showed no distinct decrease until week 
. In PMMA IMs, BMP-4 expression increased significantly from 2 
o 4 weeks (2.0 ± 0.5 vs 4.9 ± 0.6, p = 0.021), peaked at 4 weeks,
nd then decreased during week 4 to 8 (4.9 ± 0.6 vs 2.8 ± 0.3, 
 = 0.045). At 8 weeks, the expression of BMP-4 was significantly 
igher in PMMA IMs compared with BAG-S53P4 IMs (2.8 ± 0.3 vs. 
.5 ± 0.1, p = 0.001). 
Expression of BMP-7 in BAG-S53P4 IMs was high at 2 and 4 
eeks and then decreased to a low expression at 8 weeks. In 
MMA IMs, BMP-7 expression was low at 2 weeks, peaked at 4 
eeks, and persisted at 8 weeks. At 2 weeks postoperative, BAG- 468 53P4 IMs had a significantly higher BMP-7 expression compared 
ith PMMA IMs (3.4 ± 0.7 vs. 0.2 ± 0.1, p = 0.036). 
.3. Manual assessment and X-ray imaging of defects with 
AG-S53P4 scaffolds 
.3.1. Critical-sized diaphyseal defects with implanted BAG-S53P4 
caffolds can achieve stable scaffold integration and early defect 
nion 
Results of combined manual and X-ray assessments of the seg- 
ental defects with implanted BAG-S53P4 scaffolds are presented 
n Table 2 . Results at 2 and 4 weeks were heterogeneous, while all 
-week scaffolds were markedly integrated, and all 8-week defects 
emonstrated successful osteosynthesis and signs of early union. 
ig. 5 presents X-ray projections of femur samples demonstrating 
 ‘Partial integration’ at 2 weeks, the ‘Full integration’ at 4 weeks, 
nd one representative ‘Full integration’ at 8 weeks postoperative. 
he 2-week ‘Partial integration’ was stable during resection, but 
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Fig. 4. Relative gene expressions of BMP-2 (A), BMP-4 (B), and BMP-7 (C) in in- 
duced membranes. Bars show mean ± SEM. Mean relative gene expressions in in- 
duced membranes formed around BAG-S53P4 scaffolds and PMMA spacers are com- 
pared at 2, 4, and 8 weeks postoperative, and a single asterisk ( ∗) indicates differ- 
ences for which p < 0.05. 
Table 2 
Summarized results of combined manual and X-ray assessments of segmental de- 
fects with implanted BAG-S53P4 scaffolds. Qualitative evaluation of achieved scaf- 
fold integration, state of the osteosynthesis, and defect alignment as well as signs 
of early defect union at 2, 4, and 8 weeks postoperative. 
Study endpoints 
Assessment 2 weeks ( n = 3) 4 weeks ( n = 3) 8 weeks ( n = 3) 
Not integrated 2 1 - 
Partial integration 1 1 - 










Fig. 5. X-ray projections in two directions of segmental defects with implanted 
BAG-S53P4 scaffolds at 2 (A), 4 (B), and 8 (C) weeks postoperative. The resected 
femur samples are oriented with the proximal femur end positioned at the top of 












ater dislocated partially during sample transport. The 4- and 8- 
eek samples assessed as ‘Full integration’ showed no scaffold dis- 
ocation and continued to present stability and alignment during 
ostoperative handling. 
.4. SEM imaging and EDXA of BAG-S53P4 scaffolds 
.4.1. BAG-S53P4 scaffolds show internal new bone formation and 
xternal osseointegration 
SEM imaging demonstrated progressive formation of reaction 
urface and new bone inside the BAG-S53P4 scaffolds and osseoin- 
egration of the scaffolds in surrounding callus ( Fig. 6 ). Modest 469 ew bone formation was present already at 2 weeks postoperative 
ut was notably more pronounced at 4 weeks. At 8 weeks, consid- 
rable new bone formation and trabecular intergrowth of scaffold 
nd surrounding callus, namely osseointegration, had developed. 
.4.2. Bone-bonding calcium phosphate precipitate on BAG-S53P4 in 
he scaffolds 
EDXA confirmed the composition of the reaction surface formed 
n the BAG-S53P4 and the formation of new bone in the porous 
paces inside the scaffolds, as observed in SEM imaging ( Fig. 7 ). 
he reaction surface can be described as a compositional contin- 
um, with a region rich in Si closest to still remaining glass, and 
n outer region of CaP effectively bridging the Si-layer to new 
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Fig. 6. SEM backscattered electron images of implanted BAG-S53P4 scaffolds. A: Representative close-up SEM images of the center area in BAG-S53P4 scaffolds at 2 (left) and 
4 (right) weeks postoperative. Remaining BAG-S53P4 is visible as white, dense areas. Reaction surfaces are visible as grey areas with lighter peripheral rims partly covering 
the remaining BAG-S53P4 and merging into formed new woven bone inside the porous scaffold. Medullary spaces are visible as black areas. B: Corresponding SEM close-ups 
from the center area in two BAG-S53P4 scaffolds at 8 weeks postoperative. BAG-S53P4 (BAG), new bone (NB), and reaction surface (arrow) has been labeled in the left image 
to aid interpretation. C: Representative close-up SEM image of the transversal interface region where bony callus formed around the defect meets an implanted BAG-S53P4 

























one. There was a close compositional relationship between the 
aP layer and newly formed bone. 
.5. Histological assessment of BAG-S53P4 scaffolds 
.5.1. Osteoid and woven bone form inside the BAG-S53P4 scaffolds 
BAG-S53P4 scaffold samples stained with Goldner’s Masson 
richrome stain confirmed the formation of osteoid and mineral- 
zation inside the scaffolds already at 2 weeks postoperative, and 
oven bone of various magnitude at 4 and 8 weeks ( Fig. 8 ). 
At 2 weeks, reactive periosteum with ample vascularization was 
nfiltrating the scaffolds, and osteoblasts as well as foci of osteoid 
nd mineralization were found on the internal scaffold surfaces. At 
 weeks, scaffolds contained capillaries and marked woven bone 470 ormation enclosing the remaining BAG-S53P4. Focis of intramem- 
ranous ossification were found in the scaffolds, and endochon- 
ral ossification was observed in areas with possible callus exten- 
ions from reactive periosteum. New bone formed a bony network 
nside the porous scaffold. At 8 weeks, analyzable sections con- 
ained abundant vascularization and minor but assessable woven 
one formation with accumulation of osteoid and calcified matrix, 
s well as osteoblasts and osteoclasts on the glass surfaces. Sam- 
les also demonstrated progressive maturation of external callus 
hat integrated the scaffolds from 2 to 8 weeks postoperative. Soft, 
ssifying callus was present at 2 weeks, and periosteal hard callus 
t 4 weeks. At 8 weeks, samples presented remodeling hard callus 
ontaining compact bone and integrating trabeculae with vascular- 
zation and active intramembranous ossification. 
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Fig. 7. Representative energy-dispersive X-ray analysis of reaction surface and newly formed bone inside an 8-week BAG-S53P4 scaffold. Si, Na, Ca, and P levels (expressed 
as oxide compound in percent) for each measuring point (numbered as 1–8 in the SEM image to the left, and in the X-axis in the bar graph to the right) demonstrates the 
compositional continuum of the reaction surface. The reaction surface consists of a region rich in Si (measuring point 2–4) directly on the surface of remaining BAG-S53P4 
(1) and a CaP interface region (5–6) bridging into new woven bone (7–8) formed in the porous scaffold spaces. To aid interpretation, vertical lines in the graph separate the 
different areas from which the measuring points were obtained. 
Fig. 8. Close-up images of transversally cut BAG-S53P4 scaffolds stained with Goldner’s Masson trichrome stain at 2 (A–B), 4 (C), and 8 (D) weeks postoperative. New bone 
is stained blue-green, indicated by a bolded arrow in A, and osteoid is stained red-orange, indicated by a thin arrow in B. Osteoblasts are visible as cells in close proximity 
to the osteoid in B. Remaining BAG-S53P4 (white bright areas, BAG) and one large obscuring air bubble (white asterisk ∗) has been marked in the 8-week sample (D) to 
aid interpretation. Note the layered reaction surface on the remaining BAG-S53P4 in all included images (A–D). (For interpretation of the references to color in this figure 


























Unfortunately, sample preparation difficulties and air-bubble 
ormation restricted the assessment. 
.6. μCT imaging and area measurement analysis of BAG-S53P4 
caffolds 
.6.1. Osseointegration of BAG-S53P4 scaffolds progress markedly 
rom 2 to 8 weeks 
Inspection of osseointegrational development in the μCT scans 
f the resected femur samples exhibited progressive osseointegra- 
ion of the implanted BAG-S53P4 scaffolds in diaphysis ends and 
urrounding callus from 2 to 8 weeks. The integration of callus and 
efect-filling scaffold presented still incomplete but evident early 
efect bridging at 4 and 8 weeks ( Fig. 9 ). 
Osseointegration was progressing in both ends and the middle 
f the BAG-S53P4 scaffolds during follow-up. However, result ho- 
ogeneity was highly dependent on the performance of the surgi- 471 al fixation in keeping the scaffolds in place in the defects and in 
table contact with the ends of the diaphysis. 
.6.2. BAG-S53P4 decreases as reaction surface and new bone 
ncreases in the scaffolds 
Analysis of internal BAG-S53P4 scaffold area measurements 
emonstrated a significant and constant increase in new bone and 
eaction surface inside the scaffolds from 2 to 8 weeks (mean per- 
ent of total transverse scaffold area: 33.2 ± 1.9% vs. 46.1 ± 1.5%, 
 = 0.010), with a concurrent significant decrease in remaining 
lass (35.8 ± 3.9% vs. 10.4 ± 1.1%, p = 0.002) ( Fig. 10 ). Early de-
elopment during 2 to 4 weeks was similar, with a notable but not 
ignificant increase in new bone and reaction surface (33.2 ± 1.9% 
s. 40.4 ± 2.6%), and a significant decrease in remaining glass 
35.8 ± 3.9% vs. 21.2 ± 3.2%, p = 0.031). 
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Fig. 9. μCT scans of resected femur samples with implanted BAG-S53P4 scaffolds. Upper row: BAG-S53P4 scaffolds at 2 (A), 4 (B), and 8 (C) weeks postoperative. Lower row: 
μCT 3D-projection of the same 4-week BAG-S53P4 scaffold as in B in the upper row. 
Fig. 10. Analysis of area measurements obtained from μCT images of BAG-S53P4 scaffolds at 2, 4, and 8 weeks postoperative. A: Formation of new bone (NB) and reaction 
surface (RS) inside the scaffolds. B: Remaining BAG-S53P4 inside the scaffolds. Bars show mean percent (%) of the total transversal scaffold area ± SEM. ∗ indicates a 











.6.3. Reaction surface and new bone forms evenly throughout the 
AG-S53P4 scaffolds 
Comparative analysis of area measurements of new bone and 
eaction surface in different regions of the BAG-S53P4 scaffolds re- 
ealed that the formation appeared to progress similarly through- 
ut the scaffolds during the 8-week follow-up ( Fig. 11 ). During 472 eek 2 to 8, the mean percent of the total transversal scaf- 
old area occupied by new bone and reaction surface increased 
rom 33.2 ± 0.6% to 46.9 ± 0.1% in the end regions, and from 
2.8 ± 0.8% to 45.2 ± 1.2% in the middle region. No significant 
ifferences were found, and these results were consistent in the 
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Fig. 11. Formation of new bone and reaction surface in different regions of the BAG-S53P4 scaffolds from 2 to 8 weeks. Upper row: μCT images of an unused (not implanted) 
BAG-S53P4 scaffold (left) and an implanted 4-week BAG-S53P4 scaffold after femur resection (middle) along with a schematic overview of the regional segmentation for 
comparison of area measurement data in different scaffold regions (right). Lower row: Formation of new bone (NB) and reaction surface (RS) in the (distal and proximal) 
end regions (A), middle region (B), and in the whole scaffold (C) at 2, 4, and 8 weeks. The X axis presents the 9 implanted BAG-S53P4 scaffolds included in this study. For 
example, “2w1” indicates 2-week study endpoint, individual sample one. # below the X axis indicates individual scaffolds that detached during or after resection. Box plots 






























































omparative analysis of remaining BAG-S53P4 in the different scaf- 
old regions. 
.6.4. BAG-S53P4 scaffolds demonstrate intact integrity throughout 
ollow-up 
μCT imaging showed no major structural damages in the im- 
lanted BAG-S53P4 scaffolds during follow-up but revealed that 
he fixation wire protruded slightly into the 4- and 8-week scaf- 
olds ( Fig. 5 ). 
. Discussion 
This preclinical study evaluated sintered BAG-S53P4 scaffolds in 
ivo in a single-staged, one-implant IM technique for the treat- 
ent of critical-sized diaphyseal defects. In this one-implant tech- 
ique, an amorphous porous BAG-S53P4 scaffold substitutes both 
he membrane-inducing PMMA spacer and subsequent graft-filling 
n Masquelet’s original two-staged technique. We demonstrated 
hat our BAG-S53P4 scaffolds fulfill prerequisite characteristics of 
he proposed single-staged IM technique, as they produce BMP- 
xpressing IMs and osseointegrative new bone formation that an- 
hors the scaffolds in surrounding bone. Furthermore, at 8 weeks 
ostoperative all defects presented marked integration of the im- 
lanted BAG-S53P4 scaffolds as well as aligned early defect union. 
Our study found that BAG-S53P4 scaffolds do indeed produce 
Ms structurally similar to those of standard PMMA. The IMs were 
ound to be bioactive, with upregulated expressions of the potent 
steogenic growth factors BMP-2, BMP-4, and BMP-7. BMPs link 
steogenesis to angiogenesis through stimulation of osteoblasts’ 
EGF-A expression [50] , and combined expression of different 
MPs has been proposed to provide synergistic benefits [17] . Al- 
hough clinical studies characterizing gene expressions in human 
Ms are scarce, previous studies have reported upregulated expres- 
ions of BMP-2 and BMP-7 in human PMMA IMs in tibial and 473 emoral segmental defects [51] , thus indicating the importance of 
hese BMPs in IM evaluations. 
Our results presented upregulated expressions of BMP-2, BMP- 
, and BMP-7 in BAG-S53P4 IMs throughout the 8-week follow-up, 
ith peak expressions of the same magnitude as in PMMA IMs. 
nterestingly, BAG-S53P4 IMs had earlier peak expressions than 
MMA IMs. This pattern was not unambiguously statistically sig- 
ificant, but it indicates that BAG-S53P4 affects BMP expressions 
ifferently than PMMA – an intriguing finding. In BAG-S53P4 IMs, 
eak expression of BMP-2 arrived already at 2 weeks, with a sub- 
equent decrease at 4–8 weeks. In contrast, the BMP-2 expression 
n PMMA IMs was low at 2 weeks and peaked at 4–8 weeks. Ex- 
ression of BMP-4 in BAG-S53P4 IMs was high at 2–4 weeks, while 
MP-4 in PMMA IMs was high at 4 weeks and notably lower at 
 and 8 weeks. Perhaps the most striking result was the near- 
pposite BMP-7 expression pattern when comparing IMs by BAG- 
53P4 and PMMA. These differing patterns is an intriguing find 
onnected to the timing of optimal or mature osteogenic stimu- 
ation provided by the IM. In the two-staged IM technique, ma- 
ure osteogenic stimulation by the PMMA IM is considered to oc- 
ur around 6–8 weeks after the first surgery. This is in agreement 
ith our results. As PMMA is not a bone substitute, the osteogenic 
ffect provided by the IM will promote defect healing only after 
he PMMA spacer has been replaced by bone graft. The second 
urgery, in which bone graft replaces the spacer, should be per- 
ormed when the PMMA IM has reached its mature osteogenic ef- 
ect [9–13] . Hence, the actual effect of the IM on defect healing will 
egin 6–8 weeks after the first surgery. In contrast, BAG-S53P4 is 
 bone substitute and the BAG-S53P4 scaffold is continuously re- 
laced by new bone from the time of implantation, with no need 
or a second surgery or bone graft. Early peak expressions in the 
AG-S53P4 IMs indicate an early maturation of the osteogenic ef- 
ect, which promotes defect healing already from 2 weeks postop- 
rative. 
























































































































The osteogenic effect provided by the BAG-S53P4 IM also ap- 
ears well-timed when compared with the natural fracture heal- 
ng process. Similar to BAG-S53P4 IMs, natural fracture healing in- 
ludes an early peak BMP-2 expression during the first days to 
eeks to accommodate the high need for mesenchymal stem cells 
hat can differentiate into osteoprogenitor cells, and later peak ex- 
ressions of BMP-4 and BMP-7 to stimulate further bone forma- 
ion, soft callus mineralization, and maturation of woven bone and 
ony callus [52] . As critical-sized diaphyseal defects include sev- 
ral factors that undermine the natural fracture healing process, 
his timely osteogenic effect provided by the IM might offer added 
enefits through natural healing enhancement. 
To our knowledge, this is the first probative description of os- 
eogenic membranes induced by sintered amorphous BAG-S53P4 
caffolds in critical-sized defects in the femur diaphysis. Previous 
ork by Björkenheim et al. [37] study IMs of non-amorphous BAG- 
53P4 scaffolds in a non-critical defect in the femur metaphysis of 
ZW rabbits. When comparing our findings with the results re- 
orted by Björkenheim et al. [37] , both differences and similari- 
ies emerge. Both defect models show high BMP-2 expression early 
n the fracture healing process, and lower BMP-2 expressions at 4 
nd 8 weeks. Expressions of BMP-4 differs, however, as non-critical 
etaphyseal defects had a low expression at 2 weeks, while our 
ritical-sized diaphyseal model had high expressions throughout 
–4 weeks. When comparing BAG-S53P4 IMs with IMs of PMMA 
pacers, Björkenheim et al. [37] found that both implants had sim- 
lar BMP-7 expression patterns during follow-up. This contrasts the 
nverse BMP-7 expression pattern we found in critical-sized dia- 
hyseal defects. 
Dissimilar BMP-expressions at different defect sites are not a 
urprising find, as there are known differences in the healing of 
efects in the cancellous metaphysis and cortical diaphysis. The 
etaphysis is inherently rich in mesenchymal stem cells, with in- 
ammatory cells and stem cells arriving at the defect site simulta- 
eously during healing-initiation. In cortical diaphyseal defects, in- 
ammatory cells precede the stem cells [53–55] . Characterization 
f the fracture-healing cascades in different parts of the femur is 
n important part of fracture-healing optimization. 
Bioactive IMs with upregulated key BMP expressions strongly 
ndicate osteostimulative effects. Nonetheless, to be clinically use- 
ul the BAG-S53P4 scaffolds need to demonstrate formation of new 
one. To be considered osteoconductive, a prerequisite for osseoin- 
egration, new bone must also grow on the internal surfaces of the 
caffold. In this study, we confirmed osteoconductive new bone 
ormation inside the BAG-S53P4 scaffolds. Minor deposits of os- 
eoid and new bone were observed at 2 weeks and progressed 
o marked amounts of woven bone at 4 and 8 weeks postopera- 
ive. Observations were conclusive in SEM and μCT imaging, and, 
espite limited analyzable samples, also evident in histological as- 
essments. 
EDXA confirmed development of the BAG-characteristic bone- 
onding CaP layer in the scaffolds. This layer had a close compo- 
itional relationship with the new bone, establishing a tight an- 
horage. As a natural consequence of this anchorage, the separation 
f new bone and reaction surface was obstructed. Remaining BAG- 
53P4 could be clearly detected, however, thus enabling compari- 
on of remaining glass with new bone and reaction surface. Herein, 
 substitution of BAG-S53P4 into reaction surface and new bone 
merged. During the 8-week follow-up, remaining BAG-S53P4 de- 
reased significantly with a concurrent significant increase in new 
one and reaction surface. This substitution is key for the mechani- 
al stability of our model. As BAG-S53P4 is biodegradable and thus 
ecreases in volume over time, the combined success of a stable 
urgical osteosynthesis and transformation of the volume loss into 
nchoring bone is of particular importance. 474 This study also presents a more surprising find – the volume 
f new bone and reaction surface increased in a similar manner in 
ifferent scaffold regions during the 8-week follow-up. The forma- 
ion of reaction surface and new bone could be expected to vary 
n different regions, as the scaffold ends are in direct contact with 
ndogenous bone and bone marrow. This contact would presum- 
bly provide essential cells and mediators, in addition to the IM 
nflow. A conceivable explanation could be attributed to scaffold 
orosity, as it may be sufficient enough to enable body fluids, cells 
nd osteogenic growth factors to rapidly reach the middle of the 
caffolds. 
Proof of osteoconductive internal new bone formation further 
trengthens our hypothesis. However, for sintered BAG-S53P4 scaf- 
olds to be viable in the complex milieu of a large defect in 
he weight-bearing diaphysis, they also need to demonstrate suffi- 
iently stable osseointegration in surrounding bone. Osseointegra- 
ion is more durable than osteoconduction and implies that the an- 
horage between scaffold and bone is retained over time and dur- 
ng functional loading [56] . The implanted scaffold must be able to 
nchor strongly in the defect through an intergrowth of surround- 
ng bone and the bone forming inside the scaffold, aided by a suc- 
essful surgical osteosynthesis. This is critical to prevent scaffold 
etachment during postoperative loading. 
In this study, our BAG-S53P4 scaffolds exhibited limited os- 
eointegration at 2 weeks postoperative, clearly indicating that 2 
eeks was insufficient to achieve scaffold integration. Indeed, none 
f the 2-week BAG-S53P4 scaffolds were assessed as fully inte- 
rated in the combined manual and X-ray assessment. One 2-week 
caffold that was initially assessed as integrated in situ, later dis- 
ocated partially after resection – highlighting the importance of 
he combined support provided by the enclosing tissues and the 
urgical osteosynthesis during the early postoperative period. 
At 4 and 8 weeks, scaffold integration and signs of early de- 
ect union had progressed considerably. Bridging integration of the 
AG-S53P4 scaffolds into the bony callus and diaphysis ends was 
learly observed in both SEM and μCT imaging. Notably, manual 
nd X-ray assessments of 4-week scaffolds rendered heterogenic 
esults, spanning from complete scaffold detachment to a well- 
ntegrated scaffold with successful osteosynthesis and early defect 
nion. In contrast, all 8-week BAG-S53P4 scaffolds showed marked 
ntegration and all the 8-week defects demonstrated successful 
steosynthesis and early union. Thus, this study indicates that 8 
ostoperative weeks was sufficient time for the BAG-S53P4 scaf- 
olds to achieve homogeneous scaffold integration with early union 
n a critical-sized segmental defect in the femur diaphysis. In addi- 
ion, our results suggests that the BAG-S53P4 scaffolds are durable 
nough for application in these demanding defects. At present, a 
etailed mechanical scaffold characterization is ongoing and will 
e published in a later paper. 
In terms of limitations, extrapolation of animal studies into hu- 
ans is always speculative and calls for cautious interpretation. 
dditionally, our small sample number naturally interferes with 
tatistical generalizability. Nevertheless, this study presents several 
mportant considerations for optimizations in future research and 
odelling. 
Our BAG-S53P4 scaffolds were simply cylindrical, while the 
MMA spacer used in the original IM technique is shaped to wrap 
he defect ends. According to Masquelet [57] , failure to wrap the 
nds is a main pitfall of the IM technique that can lead to non- 
nions. It is indeed observable in some of our samples that while 
allus and scaffold show evident intergrowth, the callus also pro- 
rudes slightly outwards, instead of aligning to the scaffold. We 
lso found that the region where the scaffold meets the end of the 
iaphysis was the most susceptible to instability interfering with 
ntegrative bone formation. Mechanical enhancement of this inter- 









































































ace area could be beneficial, for example through development of 
 BAG-S53P4 scaffold that wraps the defect ends. 
The most challenging surgical factor conducting this study, in 
he authors’ experience, was to achieve proper fixation of the BAG- 
53P4 scaffold in the defect. A segmental, large defect in the fe- 
ur diaphysis is weight-bearing and bypasses stabilization from 
he adjacent fibula, as might benefit a tibial defect model. This 
nabled our evaluation to focus solemnly on the implanted scaf- 
old in the femur, but it also resulted in inherent instability which 
equires optimal fixation. Furthermore, while the used defect size 
as been previously established in NZW rabbits [45] , and rabbits 
re frequent in orthopedic research as their bone mineral density 
nd haversian canals are similar to humans [58 , 59] , they also have
trong hind-leg muscles affecting the femur as well as brittle cor- 
ices complicating the application of fixation hardware. 
The surgical fixation used in our model was a locking compres- 
ion plate, screws, and a wire. Although we experienced no scaf- 
old breakages and no failures of the plate fixation of the defects, 
he fixation of the scaffold itself inside the defect was clearly a pit- 
all. The scaffold fixation has to support the implant during defect 
oading until the scaffold is integrated and can assist in functional 
eight-bearing. There are a few alternatives to consider. Veterinary 
reatments of large femur fractures in NZW rabbits include plates 
nd intramedullary nailing [60 , 61] , a method also used clinically 
n humans. However, this could limit the evaluation of bone for- 
ation as the nail would occupy the scaffold center. Another op- 
ion used in humans is external fixation, but it is less suited to a 
reclinical model as it exposes the animals to unnecessary stress. 
bsorbable mesh wrapping could be considered, but it limits IM 
xamination. 
To summarize, a feasible proposal for future research would 
e an experimental model with larger animals with a femur size 
nd movement pattern more similar to humans. This should be 
ombined with a development of the scaffold to enable a surgical 
ethod with a scaffold-integrated intermedullary nail or plate fix- 
tion. In any case, optimization of the scaffold fixation is needed 
o avoid unnecessary instability and evaluate the full potential of 
hese promising BAG-S53P4 scaffolds in large weight-bearing de- 
ects, whether in a preclinical or clinical study. 
. Conclusions 
This is the first study evaluating the functional potential of 
morphous porous BAG-S53P4 scaffolds in vivo in critical-sized 
egmental diaphyseal defects treated with a single-staged version 
f Masquelets IM technique. The original two-staged IM technique 
tilizes a PMMA spacer to produce a defect-enclosing IM that 
orms the basis of the defect healing as it provides osteogenic 
ells, blood vessels, cytokines and growth factors that support bone 
ormation. When the IM has matured, the PMMA spacer is re- 
laced with bone graft which compensates for the bone loss, and 
he defect heals. To develop a single-staged IM technique, a single 
mplant that combines the original functions of both the PMMA 
pacer and the bone graft is needed. 
We demonstrated that our BAG-S53P4 scaffolds induce os- 
eostimulative defect-enclosing membranes and achieve stable 
caffold integration with early defect union in a large, weight- 
earing diaphyseal defect in rabbit femur at 4 to 8 weeks postop- 
rative. These results support the hypothesis that scaffolds sintered 
rom BAG-S53P4 are a suitable bone substitute in a single-stage IM 
echnique for the treatment of critical-sized segmental diaphyseal 
efects in long bones. Future research is needed to shed light on 
he full capacity of these scaffolds in an optimized surgical model. 475 isclosures 
Nina Lindfors is a Clinical advisor for Bonalive Biomaterials. 
eclaration of Competing Interest 
The authors declare that they have no known competing finan- 
ial interests or personal relationships that could have appeared to 
nfluence the work reported in this paper. 
cknowledgements 
We thank Bonalive Biomaterials (Turku, Finland) for kindly pro- 
iding the BAG-S53P4 granules for this study. We also thank the 
IMM Digital Microscopy and Molecular Pathology Unit supported 
y Helsinki University and Biocenter Finland, BioSiteHisto Ltd., and 
he Finnish Centre for Laboratory Animal Pathology at the De- 
artment of Veterinary Biosciences, Faculty of Veterinary Medicine, 
niversity of Helsinki for their assistance in processing, scanning, 
nd providing histological assessment of the BAG-S53P4 scaffold 
amples. This work was supported by grants provided by the Med- 
cal Society of Finland and Helsinki University Hospital. 
eferences 
[1] P.V. Giannoudis, I. Pountos, Tissue regeneration, Injury 36 (2005) S2–S5, doi: 10. 
1016/j.injury.2005.10.006 . 
[2] P.V. Giannoudis, T.A. Einhorn, D. Marsh, Fracture healing: the diamond concept, 
Injury 38 (2007) S3–S6, doi: 10.1016/S0020- 1383(08)70003- 2 . 
[3] F. Loi, L.A. Córdova, J. Pajarinen, T. Lin, Z. Yao, S.B. Goodman, Inflammation, 
fracture and bone repair, Bone 86 (2016) 119–130, doi: 10.1016/j.bone.2016.02. 
020 . 
[4] E.H. Schemitsch, Size matters: defining critical in bone defect size, J. Orthop. 
Trauma 31 (2017) S20–S22, doi: 10.1097/BOT.0 0 0 0 0 0 0 0 0 0 0 0 0978 . 
[5] J.F. Keating, A.H.R.W. Simpson, C.M. Robinson, The management of fractures 
with bone loss, J. Bone Joint Surg. Br. 87-B (2005) 142–150, doi: 10.1302/ 
0301-620X.87B2.15874 . 
[6] T.J. Blokhuis, Management of traumatic bone defects: metaphyseal versus dia- 
physeal defects, Injury 48 (2017) S91–S93, doi: 10.1016/j.injury.2017.04.021 . 
[7] G. Marongiu, A. Dolci, M. Verona, A. Capone, The biology and treatment of 
acute long-bones diaphyseal fractures: overview of the current options for 
bone healing enhancement, Bone Rep. 12 (2020) 100249, doi: 10.1016/j.bonr. 
2020.100249 . 
[8] A.C. Masquelet , F. Fitoussi , T. Begue , G.P. Muller , Reconstruction des os longs
par membrane induite et autogreffe spongieuse [Reconstruction of the long 
bones by the induced membrane and spongy autograft], Ann. Chir. Plast. Es- 
thet. 45 (20 0 0) 346–353 . 
[9] L. Vidal, C. Kampleitner, M.Á. Brennan, A. Hoornaert, P. Layrolle, Reconstruction 
of large skeletal defects: current clinical therapeutic strategies and future di- 
rections using 3D printing, Front. Bioeng. Biotechnol. 8 (2020) 61, doi: 10.3389/ 
fbioe.2020.0 0 061 . 
[10] A.C. Masquelet, T. Kishi, P.E. Benko, Very long-term results of post-traumatic 
bone defect reconstruction by the induced membrane technique, Orthop. Trau- 
matol.: Surg. Res. 105 (2019) 159–166, doi: 10.1016/j.otsr.2018.11.012 . 
[11] J.-C. Aurégan, T. Bégué, Induced membrane for treatment of critical sized bone 
defect: a review of experimental and clinical experiences, Int. Orthop. (SICOT) 
38 (2014) 1971–1978, doi: 10.10 07/s0 0264- 014- 2422- y . 
[12] A. Masquelet, N.K. Kanakaris, L. Obert, P. Stafford, P.V. Giannoudis, Bone re- 
pair using the masquelet technique, J. Bone Joint Surg. 101 (2019) 1024–1036, 
doi: 10.2106/JBJS.18.00842 . 
[13] W. Wang, K.W.K. Yeung, Bone grafts and biomaterials substitutes for bone 
defect repair: a review, Bioactive Mater. 2 (2017) 224–247, doi: 10.1016/j. 
bioactmat.2017.05.007 . 
[14] J. Patel, K.P. Gudehithlu, G. Dunea, J.A.L. Arruda, A.K. Singh, Foreign body- 
induced granulation tissue is a source of adult stem cells, Transl. Res. 155 
(2010) 191–199, doi: 10.1016/j.trsl.2009.08.010 . 
[15] P.H. Pelissier, A.C. Masquelet, R. Bareille, S.M. Pelissier, J. Amedee, Induced 
membranes secrete growth factors including vascular and osteoinductive fac- 
tors and could stimulate bone regeneration, J. Orthop. Res. 22 (2004) 73–79, 
doi: 10.1016/S0736-0266(03)00165-7 . 
[16] J.M. Wozney, V. Rosen, A.J. Celeste, L.M. Mitsock, M.L. Whitters, M.J.R.W. Kriz, 
R.M. Hewick, E.A. Wang, Novel regulators of bone formation: molecular clones 
and activities, Science 242 (1988) 1528–1534, doi: 10.1126/science.3201241 . 
[17] H. Cheng, W. Jiang, F.M. Phillips, R.C. Haydon, Y. Peng, L. Zhou, H.H. Luu, 
N. An, B. Breyer, P. Vanichakarn, J.P. Szatkowski, J.Y. Park, T.-C. He, Os- 
teogenic activity of the fourteen types of human bone morphogenetic pro- 
teins (BMPs), J. Bone Joint Surg.-Am. 85 (2003) 1544–1552, doi: 10.2106/ 
0 0 0 04623-20 03080 0 0-0 0 017 . 







































[18] P.V. Giannoudis, T.A. Einhorn, Bone morphogenetic proteins in musculoskeletal 
medicine, Injury 40 (2009) S1–S3, doi: 10.1016/S0020- 1383(09)00642- 1 . 
[19] G.M. Calori, P.V. Giannoudis, Enhancement of fracture healing with the dia- 
mond concept: the role of the biological chamber, Injury 42 (2011) 1191–1193, 
doi: 10.1016/j.injury.2011.04.016 . 
20] P.V. Giannoudis, P.J. Harwood, T. Tosounidis, N.K. Kanakaris, Restoration of long 
bone defects treated with the induced membrane technique: protocol and out- 
comes, Injury 47 (2016) S53–S61, doi: 10.1016/S0020-1383(16)30840-3 . 
[21] A. Moghaddam, B. Thaler, T. Bruckner, M. Tanner, G. Schmidmaier, Treatment 
of atrophic femoral non-unions according to the diamond concept: results of 
one- and two-step surgical procedure, J. Orthop. 14 (2017) 123–133, doi: 10. 
1016/j.jor.2016.10.003 . 
22] T.F. Raven, A. Moghaddam, C. Ermisch, F. Westhauser, R. Heller, T. Bruckner, 
G. Schmidmaier, Use of Masquelet technique in treatment of septic and at- 
rophic fracture nonunion, Injury 50 (2019) 40–54, doi: 10.1016/j.injury.2019.06. 
018 . 
23] A. Oryan, S. Alidadi, A. Moshiri, N. Maffulli, Bone regenerative medicine: classic 
options, novel strategies, and future directions, J. Orthop. Surg. Res. 9 (2014) 
18, doi: 10.1186/1749- 799X- 9- 18 . 
24] L.L. Hench, The story of Bioglass®, J. Mater. Sci.: Mater. Med. 17 (2006) 967–
978, doi: 10.1007/s10856- 006- 0432- z . 
25] L.L. Hench, H.A. Paschall, Direct chemical bond of bioactive glass-ceramic ma- 
terials to bone and muscle, J. Biomed. Mater. Res. 7 (1973) 25–42, doi: 10.1002/
jbm.820070304 . 
26] A.M. Gatti, G. Valdrè, Ö.H. Andersson, Analysis of the in vivo reactions of a 
bioactive glass in soft and hard tissue, Biomaterials 15 (1994) 208–212, doi: 10. 
1016/0142- 9612(94)90069- 8 . 
27] P. Virolainen, J. Heikkilä, A. Yli-Urpo, E. Vuorio, H.T. Aro, Histomorphometric 
and molecular biologic comparison of bioactive glass granules and autogenous 
bone grafts in augmentation of bone defect healing, J. Biomed. Mater. Res. 35 
(1997) 9–17, doi: 10.1002/(sici)1097- 4636(199704)35:1 〈 9::aid- jbm2 〉 3.0.co;2- s . 
28] V.-V. Välimäki, H.T. Aro, Molecular basis for action of bioactive glasses 
as bone graft substitute, Scand. J. Surg. 95 (2006) 95–102, doi: 10.1177/ 
145749690609500204 . 
29] A. Hoppe, N.S. Güldal, A.R. Boccaccini, A review of the biological response to 
ionic dissolution products from bioactive glasses and glass-ceramics, Biomate- 
rials 32 (2011) 2757–2774, doi: 10.1016/j.biomaterials.2011.01.004 . 
30] E. Munukka, O. Leppäranta, M. Korkeamäki, M. Vaahtio, T. Peltola, D. Zhang, 
L. Hupa, H. Ylänen, J.I. Salonen, M.K. Viljanen, E. Eerola, Bactericidal effects of 
bioactive glasses on clinically important aerobic bacteria, J. Mater. Sci.: Mater. 
Med. 19 (2008) 27–32, doi: 10.1007/s10856- 007- 3143- 1 . 
[31] J.S. Fernandes, P. Gentile, R.A. Pires, R.L. Reis, P.V. Hatton, Multifunctional 
bioactive glass and glass-ceramic biomaterials with antibacterial properties 
for repair and regeneration of bone tissue, Acta Biomater. 59 (2017) 2–11, 
doi: 10.1016/j.actbio.2017.06.046 . 
32] N.A.P. van Gestel, J. Geurts, D.J.W. Hulsen, B. van Rietbergen, S. Hofmann, 
J.J. Arts, Clinical applications of S53P4 bioactive glass in bone healing and os- 
teomyelitic treatment: a literature review, Biomed. Res. Int. 2015 (2015) 1–12, 
doi: 10.1155/2015/6 84 826 . 
33] I. Gergely , Ö. Nagy , Zagyva Ancu ̧t a , S. Gy. Zuh , O.M. Russu , Our short-term ex-
perience with the use of S53P4 (BonAlive®) bioactive glass as a bone graft 
substitute, Acta Medica Marisiensis 57 (2011) 627–630 . 
34] N.C. Lindfors, I. Koski, J.T. Heikkilä, K. Mattila, A.J. Aho, A prospective random- 
ized 14-year follow-up study of bioactive glass and autogenous bone as bone 
graft substitutes in benign bone tumors, J. Biomed. Mater. Res. 9999B (2010) 
NA-NA, doi: 10.1002/jbm.b.31636 . 
35] M.C. Tanner, R. Heller, F. Westhauser, M. Miska, T. Ferbert, C. Fischer, S. Gantz, 
G. Schmidmaier, P. Haubruck, Evaluation of the clinical effectiveness of bioac- 
tive glass (S53P4) in the treatment of non-unions of the tibia and femur: study 
protocol of a randomized controlled non-inferiority trial, Trials 19 (2018) 299, 
doi: 10.1186/s13063-018-2681-9 . 
36] R. Björkenheim, G. Strömberg, J. Pajarinen, M. Ainola, P. Uppstu, L. Hupa, 
T.O. Böhling, N.C. Lindfors, Polymer-coated bioactive glass S53P4 increases 
VEGF and TNF expression in an induced membrane model in vivo, J. Mater. 
Sci. 52 (2017) 9055–9065, doi: 10.1007/s10853- 017- 0839- 6 . 
37] R. Björkenheim, G. Strömberg, M. Ainola, P. Uppstu, L. Aalto-Setälä, L. Hupa, 
J. Pajarinen, N.C. Lindfors, Bone morphogenic protein expression and bone for- 
mation are induced by bioactive glass S53P4 scaffolds in vivo, J. Biomed. Mater. 
Res. 107 (2019) 847–857, doi: 10.1002/jbm.b.34181 . 
38] J.R. Jones, Reprint of: review of bioactive glass: from hench to hybrids, Acta 
Biomater. 23 (2015) S53–S82, doi: 10.1016/j.actbio.2015.07.019 . 476 39] J. Massera, L. Hupa, Influence of SrO substitution for CaO on the properties of 
bioactive glass S53P4, J. Mater. Sci.: Mater. Med. 25 (2014) 657–668, doi: 10. 
1007/s10856- 013- 5120- 1 . 
40] L. Aalto-Setälä, P. Uppstu, P. Sinytsyna, N.C. Lindfors, L. Hupa, Amorphous 
S53P4 glass scaffolds for in vivo applications, Manuscript in preparation. 
(2020). 
[41] S. Fagerlund, J. Massera, N. Moritz, L. Hupa, M. Hupa, Phase composition and 
in vitro bioactivity of porous implants made of bioactive glass S53P4, Acta Bio- 
mater. 8 (2012) 2331–2339, doi: 10.1016/j.actbio.2012.03.011 . 
42] Editor(s): J. Heikkilä, 8 - Use of bioactive glasses as bone substitutes in or- 
thopaedics and traumatology, in: Heimo O. Ylänen (Ed.), Woodhead Pub- 
lishing Series in Biomaterials, Bioactive Glasses, Woodhead Publishing, 2011, 
pp. 189–208. ISBN 9781845697686 . 
43] C.-Y. Lin, Y.-H. Chang, K.-J. Lin, T.-C. Yen, C.-L. Tai, C.-Y. Chen, W.-H. Lo, I.-
T. Hsiao, Y.-C. Hu, The healing of critical-sized femoral segmental bone defects 
in rabbits using baculovirus-engineered mesenchymal stem cells, Biomaterials 
31 (2010) 3222–3230, doi: 10.1016/j.biomaterials.2010.01.030 . 
44] K.-T. Peng, M.-Y. Hsieh, C.T. Lin, C.-F. Chen, M.S. Lee, Y.-Y. Huang, P.-J. Chang, 
Treatment of critically sized femoral defects with recombinant BMP-2 deliv- 
ered by a modified mPEG-PLGA biodegradable thermosensitive hydrogel, BMC 
Musculoskelet Disord. 17 (2016) 286, doi: 10.1186/s12891- 016- 1131- 7 . 
45] M.J. Concannon, M.T. Boschert, C.L. Puckett, Bone induction using demineral- 
ized bone in the rabbit femur: a long-term study, Plast. Reconstr. Surg. 99 
(June (7)) (1997) 1983–1988, doi: 10.1097/0 0 0 06534-1997060 0 0-0 0 025 . 
46] T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative 
C(T) method, Nat. Protoc. 3 (2008) 1101–1108, doi: 10.1038/nprot.2008.73 . 
[47] M.L. McHugh, Multiple comparison analysis testing in ANOVA, Biochem. Med. 
(2011) 203–209, doi: 10.11613/BM.2011.029 . 
48] A. Hazra, N. Gogtay, Biostatistics series module 3: comparing groups: numeri- 
cal variables, Indian J. Dermatol. 61 (2016) 251, doi: 10.4103/0019-5154.182416 . 
49] K. Rani Das, A brief review of tests for normality, AJTAS 5 (2016) 5, doi: 10.
11648/j.ajtas.20160501.12 . 
50] M.M.L. Deckers, R.L.V. Bezooijen, J. Hoogendam, Bone morphogenetic proteins 
stimulate angiogenesis through osteoblast-derived vascular endothelial growth 
factor A, Endocrinology 143 (2002) 1545–1553, doi: 10.1210/endo.143.4.8719 . 
[51] H.E. Gruber, G. Ode, J. Ingram, S. Bethea, M.J. Bosse, Osteogenic, stem cell 
and molecular characterisation of the human induced membrane from extrem- 
ity bone defects, Bone Joint Res. 5 (2016) 106–115, doi: 10.1302/2046-3758.54. 
20 0 0483 . 
52] M. Bernhardsson, P. Aspenberg, Osteoblast precursors and inflammatory cells 
arrive simultaneously to sites of a trabecular-bone injury, Acta Orthopaedica 
89 (2018) 457–461, doi: 10.1080/17453674.2018.14 816 82 . 
53] T. Ono, H. Takayanagi, Osteoimmunology in bone fracture healing, Curr. Osteo- 
poros. Rep. 15 (2017) 367–375, doi: 10.1007/s11914- 017- 0381- 0 . 
54] K. Kumagai, A. Vasanji, J.A. Drazba, R.S. Butler, G.F. Muschler, Circulating cells 
with osteogenic potential are physiologically mobilized into the fracture heal- 
ing site in the parabiotic mice model, J. Orthop. Res. 26 (2008) 165–175, 
doi: 10.1002/jor.20477 . 
55] R. Dimitriou, E. Tsiridis, P.V. Giannoudis, Current concepts of molecular aspects 
of bone healing, Injury 36 (2005) 1392–1404, doi: 10.1016/j.injury.2005.07.019 . 
56] T. Albrektsson, C. Johansson, Osteoinduction, osteoconduction and osseointe- 
gration, Eur. Spine J. 10 (2001) 96–101, doi: 10.10 07/s0 0586010 0282 . 
57] A.C. Masquelet, Induced membrane technique: pearls and pitfalls, J. Orthop. 
Trauma 31 (2017) 36–38, doi: 10.1097/BOT.0 0 0 0 0 0 0 0 0 0 0 0 0979 . 
58] A. Schafrum Macedo, C. Cezaretti Feitosa, F. Yoiti Kitamura Kawamoto, P. Vini- 
cius Tertuliano Marinho, Í.dos Santos Dal-Bó, B. Fiuza Monteiro, L. Prado, 
T. Bregadioli, G. Antonio Covino Diamante, C. Ricardo Auada Ferrigno, Animal 
modeling in bone research—should we follow the white rabbit? Anim. Models 
Exp. Med. 2 (2019) 162–168, doi: 10.1002/ame2.12083 . 
59] Y. Li, S.-K. Chen, L. Li, L. Qin, X.-L. Wang, Y.-X. Lai, Bone defect animal models
for testing efficacy of bone substitute biomaterials, J. Orthop. Transl. 3 (2015) 
95–104, doi: 10.1016/j.jot.2015.05.002 . 
60] J.D. Reuter , S. Ovadia , P. Howell , D.H. Jaskwich , Femoral fracture repair and
postoperative management in New Zealand white rabbits, Contemp. Top. Lab. 
Anim. Sci. 41 (2002) 49–52 PMID: 12109898 . 
61] M. Crigel, M. Balligand, Critical size defect model on the femur in rabbits, Vet. 
Compart. Orthop. Traumatol. 15 (2002) 158–163, doi: 10.1055/s- 0038- 1632731 . 
